The question for Lilly, and for every innovator playing in India's weight-loss drug sector is: How much of the global model needs to be rebuilt for a market where innovation opens the door, but price decides who walks through it?
For hematocrit and reticulocyte counts, recommendations are to repeat these tests daily from the 5th to 7th days of treatment and then frequently until the hematocrit returns to a normal range (11, 14, 15)
Clinically Backed Probiotic Strains for Dual Action Support Not all bacteria are created equal
By now, the pH conflict is minimized, and the skin is perfectly prepped for maximum absorption
What the evidence supports: Injectable semaglutide was undetectable in breast milk from eight nursing mothers at doses up to 1 mg weekly Injectable tirzepatide was undetectable in approximately 96 percent of milk samples from 11 nursing mothers at 5 mg doses Both medications have molecular weights (4,114 and 4,813 Daltons) that make significant milk transfer biologically unlikely Any trace amounts in milk would have negligible oral bioavailability in the infant No adverse infant effects were observed in any of the lactation studies LactMed states tirzepatide is not a reason to discontinue breastfeeding What the evidence does not support: Use of oral semaglutide (Rybelsus) during breastfeeding due to the absorption enhancer SNAC Use of any GLP-1 agonist without physician supervision during lactation Aggressive weight loss goals (more than 1 to 1.5 pounds per week) while breastfeeding Assumption that compounded formulations carry the same safety profile as pharmaceutical-grade products without specific data What remains unknown: Safety at higher therapeutic doses (semaglutide above 1 mg, tirzepatide above 5 mg) Long-term infant outcomes from maternal GLP-1 exposure during breastfeeding Effects on breast milk composition and nutritional quality Safety of newer GLP-1 agonists like retatrutide The decision is ultimately yours and your physician's
These findings provide preclinical validation for the use of anti-GIPR antibodies in the treatment of obesity
